Yu Kumazaki
Papers
1
Total Citations
7
H-Index
1
About
Yu Kumazaki is a radiation oncology researcher whose work centers on improving treatment precision and reducing toxicity in prostate cancer radiotherapy. Her most cited study investigates rectal toxicity following extremely hypofractionated radiotherapy (EHF-RT) delivered via a non-isocentric robotic radiosurgery system for early-stage prostate cancer. This feasibility study, published in 2016, established critical safety benchmarks for high-dose, ultra-short radiation regimens, demonstrating that such approaches could be administered with acceptable rectal side effects in carefully selected patients aged 50–84 with low- to intermediate-risk disease. By systematically evaluating dose constraints and toxicity outcomes, Kumazaki’s work has contributed to the broader adoption of stereotactic body radiotherapy (SBRT) techniques in prostate cancer management. Her findings help clinicians balance tumor control with organ preservation, directly impacting treatment protocols for thousands of patients annually. While her citation count reflects the specialized nature of her research, her contributions are foundational to the ongoing refinement of hypofractionation schedules. Kumazaki’s dedication to evidence-based radiation oncology continues to shape safer, more effective prostate cancer therapies.
Research Focus
Key Achievements
Top Papers
- 1